Literature DB >> 29212939

The Heptad Repeat C Domain of the Respiratory Syncytial Virus Fusion Protein Plays a Key Role in Membrane Fusion.

Imogen M Bermingham1, Keith J Chappell1, Daniel Watterson1, Paul R Young2,3.   

Abstract

Respiratory syncytial virus (RSV) mediates host cell entry through the fusion (F) protein, which undergoes a conformational change to facilitate the merger of viral and host lipid membrane envelopes. The RSV F protein comprises a trimer of disulfide-bonded F1 and F2 subunits that is present on the virion surface in a metastable prefusion state. This prefusion form is readily triggered to undergo refolding to bring two heptad repeats (heptad repeat A [HRA] and HRB) into close proximity to form a six-helix bundle that stabilizes the postfusion form and provides the free energy required for membrane fusion. This process can be triggered independently of other proteins. Here, we have performed a comprehensive analysis of a third heptad repeat region, HRC (amino acids 75 to 97), an amphipathic α-helix that lies at the interface of the prefusion F trimer and is a major structural feature of the F2 subunit. We performed alanine scanning mutagenesis from Lys-75 to Met-97 and assessed all mutations in transient cell culture for expression, proteolytic processing, cell surface localization, protein conformation, and membrane fusion. Functional characterization revealed a striking distribution of activity in which fusion-increasing mutations localized to one side of the helical face, while fusion-decreasing mutations clustered on the opposing face. Here, we propose a model in which HRC plays a stabilizing role within the globular head for the prefusion F trimer and is potentially involved in the early events of triggering, prompting fusion peptide release and transition into the postfusion state.IMPORTANCE RSV is recognized as the most important viral pathogen among pediatric populations worldwide, yet no vaccine or widely available therapeutic treatment is available. The F protein is critical for the viral replication process and is the major target for neutralizing antibodies. Recent years have seen the development of prefusion stabilized F protein-based approaches to vaccine design. A detailed understanding of the specific domains and residues that contribute to protein stability and fusion function is fundamental to such efforts. Here, we present a comprehensive mutagenesis-based study of a region of the RSV F2 subunit (amino acids 75 to 97), referred to as HRC, and propose a role for this helical region in maintaining the delicate stability of the prefusion form.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  fusion; heptad repeat; membrane fusion; mutagenesis; respiratory syncytial virus

Mesh:

Substances:

Year:  2018        PMID: 29212939      PMCID: PMC5790940          DOI: 10.1128/JVI.01323-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Post-translational processing and oligomerization of the fusion glycoprotein of human respiratory syncytial virus.

Authors:  P L Collins; G Mottet
Journal:  J Gen Virol       Date:  1991-12       Impact factor: 3.891

2.  Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus.

Authors:  R M Hendry; J C Burns; E E Walsh; B S Graham; P F Wright; V G Hemming; W J Rodriguez; H W Kim; G A Prince; K McIntosh
Journal:  J Infect Dis       Date:  1988-04       Impact factor: 5.226

3.  Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion.

Authors:  D M Lambert; S Barney; A L Lambert; K Guthrie; R Medinas; D E Davis; T Bucy; J Erickson; G Merutka; S R Petteway
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

4.  Soluble respiratory syncytial virus fusion protein in the fully cleaved, pretriggered state is triggered by exposure to low-molarity buffer.

Authors:  Supranee Chaiwatpongsakorn; Raquel F Epand; Peter L Collins; Richard M Epand; Mark E Peeples
Journal:  J Virol       Date:  2011-02-09       Impact factor: 5.103

5.  Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention.

Authors:  Margarita Magro; Vicente Mas; Keith Chappell; Mónica Vázquez; Olga Cano; Daniel Luque; María C Terrón; José A Melero; Concepción Palomo
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-08       Impact factor: 11.205

6.  Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity.

Authors:  R A Olmsted; N Elango; G A Prince; B R Murphy; P R Johnson; B Moss; R M Chanock; P L Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

7.  Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody.

Authors:  Jason S McLellan; Man Chen; Sherman Leung; Kevin W Graepel; Xiulian Du; Yongping Yang; Tongqing Zhou; Ulrich Baxa; Etsuko Yasuda; Tim Beaumont; Azad Kumar; Kayvon Modjarrad; Zizheng Zheng; Min Zhao; Ningshao Xia; Peter D Kwong; Barney S Graham
Journal:  Science       Date:  2013-04-25       Impact factor: 47.728

8.  Elevated temperature triggers human respiratory syncytial virus F protein six-helix bundle formation.

Authors:  Abdul S Yunus; Trent P Jackson; Katherine Crisafi; Irina Burimski; Nicole R Kilgore; Dorian Zoumplis; Graham P Allaway; Carl T Wild; Karl Salzwedel
Journal:  Virology       Date:  2009-11-18       Impact factor: 3.616

9.  A monomeric uncleaved respiratory syncytial virus F antigen retains prefusion-specific neutralizing epitopes.

Authors:  Kurt A Swanson; Kara Balabanis; Yuhong Xie; Yukti Aggarwal; Concepción Palomo; Vicente Mas; Claire Metrick; Hui Yang; Christine A Shaw; José A Melero; Philip R Dormitzer; Andrea Carfi
Journal:  J Virol       Date:  2014-07-30       Impact factor: 5.103

10.  A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism.

Authors:  Anders Krarup; Daphné Truan; Polina Furmanova-Hollenstein; Lies Bogaert; Pascale Bouchier; Ilona J M Bisschop; Myra N Widjojoatmodjo; Roland Zahn; Hanneke Schuitemaker; Jason S McLellan; Johannes P M Langedijk
Journal:  Nat Commun       Date:  2015-09-03       Impact factor: 14.919

View more
  2 in total

1.  Third Helical Domain of the Nipah Virus Fusion Glycoprotein Modulates both Early and Late Steps in the Membrane Fusion Cascade.

Authors:  J Lizbeth Reyes Zamora; Victoria Ortega; Gunner P Johnston; Jenny Li; Nicole M André; I Abrrey Monreal; Erik M Contreras; Gary R Whittaker; Hector C Aguilar
Journal:  J Virol       Date:  2020-09-15       Impact factor: 5.103

2.  Intranasal vaccination with a recombinant protein CTA1-DD-RBF protects mice against hRSV infection.

Authors:  Hai Li; Hu Ren; Yan Zhang; Lei Cao; Wenbo Xu
Journal:  Sci Rep       Date:  2021-09-20       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.